1887

Chapter 75 : Susceptibility Test Methods: Anaerobic Bacteria*

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Susceptibility Test Methods: Anaerobic Bacteria*, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817381/9781555817381.ch75-1.gif /docserver/preview/fulltext/10.1128/9781555817381/9781555817381.ch75-2.gif

Abstract:

Infections due to anaerobic bacteria are common and have the capacity to be life threatening. Anaerobic bacterial resistance is increasing globally among many different anaerobes for a wide range of antibiotics. Thus, clinicians and laboratorians can no longer assume susceptibility of anaerobes without performing the testing. Various methods of susceptibility testing are reviewed in this chapter, including the Clinical and Laboratory Standards Institute (CLSI) agar dilution and broth microdilution methods. Additionally, commercial methods of susceptibility testing for anaerobes are discussed. The advantages and disadvantages of each testing method are emphasized. Specific patterns of resistance are covered for Gram-negative and Gram-positive anaerobes. Finally, specific recommendations for antibiotic testing and reporting, including the use of susceptibility antibiograms, are presented.

Citation: Schuetz A, Hecht D. 2015. Susceptibility Test Methods: Anaerobic Bacteria*, p 1342-1355. In Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, Warnock D (ed), Manual of Clinical Microbiology, Eleventh Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817381.ch75
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555817381.mcm11.ch75
1. Salonen JH,, Eerola E,, Meurman O. 1988. Clinical significance and outcome of anaerobic bacteremia. Clin Infect Dis 26:14131417.
2. Japanese Society of Chemotherapy Committee on Guidelines for Treatment of Anaerobic Infections; Japanese Association for Anaerobic InfectionResearch. 2011. Chapter 1-3. Anaerobic infections (general): drug susceptibility tests. J Infect Chemother 17:2630.
3. Nagy E,, Urbán E,, Nord CE,, ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. 2011. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience. Clin Microbiol Infect 17:371379.
4. Snydman DR,, Jacobus NV,, McDermott LA,, Golan Y,, Hecht DW,, Goldstein EJ,, Harrell L,, Jenkins S,, Newton D,, Pierson C,, Rihs JD,, Yu VL,, Venezia R,, Finegold SM,, Rosenblatt JE,, Gorbach SL. 2010. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005–2007). Clin Infect Dis 50(Suppl 1):S26S33.
5. Roberts SA,, Shore KP,, Paviour SD,, Holland D,, Morris AJ. 2006. Antimicrobial susceptibility of anaerobic bacteria in New Zealand: 1999–2003. J Antimicrob Chemother 57:992998.
6. Karlowsky JA,, Walkty AJ,, Adam HJ,, Baxter MR,, Hoban DJ,, Zhanel GG. 2012. Prevalence of antimicrobial resistance among clinical isolates of Bacteroides fragilis group in Canada in 2010-2011: CANWARD surveillance study. Antimicrob Agents Chemother 56:12471252.
7. CLSI. 2012. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard, 8th ed. CLSI M11-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
8. CLSI. 2014. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement. CLSI M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Jousimies-Somer HR,, Summanen P,, Citron DM,, Baron EJ,, Wexler HM,, Finegold SM. 2002. Wadsworth-KTL Anaerobic Bacteriology Manual, 6th ed. Star Publishing Company, Belmont, CA.
10. Roe DE,, Finegold SM,, Citron DM,, Goldstein EJ,, Wexler HM,, Rosenblatt JE,, Cox ME,, Jenkins SG,, Hecht DW. 2002. Multilaboratory comparison of growth characteristics for anaerobes, using 5 different agar media. Clin Infect Dis 35:S36S39.
11. Steers E,, Foltz EL,, Graves BS. 1959. An inocula replicating apparatus for routine testing of bacterial susceptibility to antibiotics. Antibiot Chemother 9:307311. In CLSI. 2012. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard, 8th ed. CLSI M11-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Hindler JF,, Tamashiro L,. 2007. Preparation of broth microdilution MIC trays, p 5.15.15.15.18. In Garcia LS,, Isenberg HD (ed), Clinical Microbiology Procedures Handbook, 3rd ed. ASM Press, Washington, DC.
13. Goldstein EJ,, Citron DM,, Goldman PJ,, Goldman RJ. 2008. National hospital survey of anaerobic culture and susceptibility methods: III. Anaerobe 14:6872.
14. Bolmström A,, Karlsson A,, Engelhardt A,, Ho P,, Petersen PJ,, Bradford PA,, Jones CH. 2007. Validation and reproducibility assessment of tigecycline MIC determinations by Etest. J Clin Microbiol 45:24742479.
15. Citron DM,, Ostovari MI,, Karlsson A,, Goldstein EJ. 1991. Evaluation of the E test for susceptibility testing of anaerobic bacteria. J Clin Microbiol 29:21972203.
16. Rosenblatt JE,, Gustafson DR. 1995. Evaluation of the Etest for susceptibility testing of anaerobic bacteria. Diagn Microbiol Infect Dis 22:279284.
17. Poulet PP,, Duffaut D,, Lodter JP. 1999. Evaluation of the Etest for determining the in-vitro susceptibilities of Prevotella intermedia isolates to metronidazole. J Antimicrob Chemother 43:610611.
18. Croco JL,, Erwin ME,, Jennings JM,, Putnam LR,, Jones RN. 1994. Evaluation of the Etest for antimicrobial spectrum and potency determinations of anaerobes associated with bacterial vaginosis and peritonitis. Diagn Microbiol Infect Dis 20:213219.
19. Cormican MG,, Erwin ME,, Jones RN. 1996. False resistance to metronidazole by E-test among anaerobic bacteria investigations of contributing test conditions and medium quality. Diagn Microbiol Infect Dis 24:117119.
20. Rennie RP,, Turnbull L,, Brosnikoff C,, Cloke J. 2012. First comprehensive evaluation of the M.I.C. Evaluator device compared to Etest and CLSI reference dilution methods for antimicrobial susceptibility testing of clinical strains of anaerobes and other fastidious bacterial species. J Clin Microbiol 50:11531157.
21. Dowzicky MJ,, Nadler HL,, Sheikh W. 1994. Comparison of Sensititre broth microdilution and agar dilution susceptibility testing techniques for meropenem to determine accuracy, reproducibility, and predictive values. J Clin Microbiol 32:22042207.
22. Wexler HM. 2007. Bacteroides: the good, the bad, and the nitty-gritty. Clin Microbiol Rev 20:593621.
23. Dubreuil L,, Odou MF. 2010. Anaerobic bacteria and antibiotics: what kind of unexpected resistance could I find in my laboratory tomorrow? Anaerobe 16:555559.
24. Fernández-Canigia L,, Litterio M,, Legaria MC,, Castello L,, Predari SC,, Di Martino A,, Rossetti A,, Rollet R,, Carloni G,, Bianchini H,, Cejas D,, Radice M,, Gutkind G,, Anaerobe Surveillance Team. 2012. First national survey of antibiotic susceptibility of the Bacteroides fragilis group: emerging resistance to carbapenems in Argentina. Antimicrob Agents Chemother 56:13091314.
25. Seifert H,, Dalhoff A,, PRISMA Study Group. 2010. German multicentre survey of the antibiotic susceptibility of Bacteroides fragilis group and Prevotella species isolated from intra-abdominal infections: results from the PRISMA study. J Antimicrob Chemother 65:24052410.
26. Boente RF,, Ferreira LQ,, Falcão LS,, Miranda KR,, Guimarães PL,, Santos-Filho J,, Vieira JM,, Barroso DE,, Emond JP,, Ferreira EO,, Paula GR,, Domingues RM. 2010. Detection of resistance genes and susceptibility patterns in Bacteroides and Parabacteroides strains. Anaerobe 16:190194.
27. Aldridge KE,, Ashcraft D,, O’Brien M,, Sanders CV. 2003. Bacteremia due to Bacteroides fragilis group: distribution of species, beta-lactamase production, and antimicrobial susceptibility patterns. Antimicrob Agents Chemother 47:148153.
28. Treviño M,, Areses P,, Peñalver MD,, Cortizo S,, Pardo F,, del Molino ML,, García-Riestra C,, Hernández M,, Llovo J,, Regueiro BJ. 2012. Susceptibility trends of Bacteroides fragilis group and characterization of carbapenemase-producing strains by automated REP-PCR and MALDI TOF. Anaerobe 18:3743.
29. Snydman DR,, Jacobus NV,, McDermott LA,, Golan Y,, Goldstein EJ,, Harrell L,, Jenkins S,, Newton D,, Pierson C,, Rosenblatt J,, Venezia R,, Gorbach SL,, Queenan AM,, Hecht DW. 2011. Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006–2009. Anaerobe 17:147151.
30. Jamal W,, Shahin M,, Rotimi VO. 2010. Surveillance and trends of antimicrobial resistance among clinical isolates of anaerobes in Kuwait hospitals from 2002 to 2007. Anaerobe 16:15.
31. Liu CY,, Huang YT,, Liao CH,, Yen LC,, Lin HY,, Hsueh PR. 2008. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob Agents Chemother 52:31613168.
32. Wybo I,, Pierard D,, Verschraegen I,, Reynders M,, Vandoorslaer K,, Claeys G,, Delmee M,, Glupczynski Y,, Gordts B,, Ieven M,, Melin P,, Struelens M,, Verhaegen J,, Lauwers S. 2007. Third Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria. J Antimicrob Chemother 59:132139.
33. Behra-Miellet J,, Calvet L,, Dubreuil L. 2004. A Bacteroides thetaiotaomicron porin that could take part in resistance to beta-lactams. Int J Antimicrob Agents 24:135143.
34. Garcia N,, Gutierrez G,, Lorenzo M,, Garcia JE,, Piriz S,, Quesada A. 2008. Genetic determinants for cfxA expression in Bacteroides strains isolated from human infections. J Antimicrob Chemother 62:942947.
35. Piriz S,, Vadillo S,, Quesada A,, Criado J,, Cerrato R,, Ayala J. 2004. Relationship between penicillin-binding protein patterns and beta-lactamases in clinical isolates of Bacteroides fragilis with different susceptibility to beta-lactam antibiotics. J Med Microbiol 53:213221.
36. Aldridge KE,, Ashcraft D,, Cambre K,, Pierson CL,, Jenkins SG,, Rosenblatt JE. 2001. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob Agents Chemother 45:12381243.
37. Snydman DR,, Jacobus NV,, McDermott LA,, Supran S,, Cuchural GJJr,, Finegold S,, Harrell L,, Hecht DW,, Iannini P,, Jenkins S,, Pierson C,, Rihs J,, Gorbach SL. 1999. Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996. Antimicrob Agents Chemother 43:24172422.
38. Sherwood JE,, Fraser S,, Citron DM,, Wexler H,, Blakely G,, Jobling K,, Patrick S. 2011. Multi-drug resistant Bacteroides fragilis recovered from blood and severe leg wounds caused by an improvised explosive device (IED) in Afghanistan. Anaerobe 17:152155.
39. Soki J,, Edwards R,, Hedberg M,, Fang H,, Nagy E,, Nord CE. 2006. Examination of cfiA-mediated carbapenem resistance in Bacteroides fragilis strains from a European antibiotic susceptibility survey. Int J Antimicrob Agents 28:497502.
40. Toprak NU,, Uzunkaya OD,, Sóki J,, Soyletir G. 2012. Susceptibility profiles and resistance genes for carbapenems (cfiA) and metronidazole (nim) among Bacteroides species in a Turkish University Hospital. Anaerobe 18:169171.
41. Roberts MC,, Sutcliffe J,, Courvalin P,, Jensen LB,, Rood J,, Seppala H. 1999. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob Agents Chemother 43:28232830.
42. Gal M,, Brazier JS. 2004. Metronidazole resistance in Bacteroides spp. carrying nim genes and the selection of slow-growing metronidazole-resistant mutants. J Antimicrob Chemother 54:109116.
43. Löfmark S,, Fang H,, Hedberg M,, Edlund C. 2005. Inducible metronidazole resistance and nim genes in clinical Bacteroides fragilis group isolates. Antimicrob Agents Chemother 49:12531256.
44. Nagy E,, Dowzicky MJ. 2010. In vitro activity of tigecycline and comparators against a European compilation of anaerobes collected as part of the Tigecycline Evaluation and Surveillance Trial (TEST). Scand J Infect Dis 42:3338.
45. Nguyen MH,, Yu VL,, Morris AJ,, McDermott L,, Wagener MW,, Harrell L,, Snydman DR. 2000. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clin Infect Dis 30:870876.
46. Papaparaskevas J,, Pantazatou A,, Katsandri A,, Legakis NJ,, Avlamis A. 2005. Multicentre survey of the in-vitro activity of seven antimicrobial agents, including ertapenem, against recently isolated Gram-negative anaerobic bacteria in Greece. Clin Microbiol Infect 11:820824.
47. Wybo I,, Van den Bossche D,, Soetens O,, Vekens E,, Vandoorslaer K,, Claeys G,, Glupczynski Y,, Ieven M,, Melin P,, Nonhoff C,, Rodriguez-Villalobos H,, Verhaegen J,, Piérard D. 2013. Fourth Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria. J Antimicrob Chemother 69:155161.
48. Bahar H,, Torun MM,, Demirci M,, Kocazeybek B. 2005. Antimicrobial resistance and beta-lactamase production of clinical isolates of Prevotella and Porphyromonas species. Chemotherapy 51:914.
49. Pelak BA,, Citron DM,, Motyl M,, Goldstein EJ,, Woods GL,, Teppler H. 2002. Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection. J Antimicrob Chemother 50:735741.
50. Alauzet C,, Mory F,, Teyssier C,, Hallage H,, Carlier JP,, Grollier G,, Lozniewski A. 2010. Metronidazole resistance in Prevotella spp. and description of a new nim gene in Prevotella baroniae. Antimicrob Agents Chemother 54:6064.
51. Goldstein EJ,, Citron DM,, Merriam CV,, Warren YA,, Tyrrell KL,, Fernandez HT. 2006. In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections. Antimicrob Agents Chemother 50:39593962.
52. Koeth LM,, Good CE,, Appelbaum PC,, Goldstein EJ,, Rodloff AC,, Claros M,, Dubreuil LJ. 2004. Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents. J Antimicrob Chemother 53:10391044.
53. Summanen P,, Wexler HM,, Finegold SM. 1992. Antimicrobial susceptibility testing of Bilophila wadsworthia by using triphenyltetrazolium chloride to facilitate endpoint determination. Antimicrob Agents Chemother 36:16581664.
54. King A,, Downes J,, Nord CE,, Phillips I. 1999. Antimicrobial susceptibility of non-Bacteroides fragilis group anaerobic gram-negative bacilli in Europe. Clin Microbiol Infect 5:404416.
55. Finegold SM,, Song Y,, Liu C. 2002. Taxonomy—general comments and update on taxonomy of clostridia and anaerobic cocci. Anaerobe 8:283285.
56. Molitoris E,, Wexler HM,, Finegold SM. 1997. Sources and antimicrobial susceptibilities of Campylobacter gracilis and Sutterella wadsworthensis. Clin Infect Dis 25:S264S265.
57. Goldstein EJC,, Citron DM. 2011. Resistance trends in antimicrobial susceptibility of anaerobic bacteria, part I. Clin Microbiol Newsl 33:18.
58. Oprica C,, Nord CE. 2005. European surveillance study on the antibiotic susceptibility of Propionibacterium acnes. Clin Microbiol Infect 11:204213.
59. Tyrrell KL,, Citron DM,, Warren YA,, Fernandez HT,, Merriam CV,, Goldstein EJ. 2006. In vitro activities of daptomycin, vancomycin, and penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes. Antimicrob Agents Chemother 50:27282731.
60. Goldstein EJ,, Citron DM,, Merriam CV,, Warren Y,, Tyrrell K,, Fernandez HT. 2003. In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria. Antimicrob Agents Chemother 47:19681971.
61. CLSI. 2010. Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved Guideline, 2nd ed. CLSI M45-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
62. Salminen MK,, Rautelin H,, Tynkkynen S,, Poussa T,, Saxelin M,, Valtonen V,, Jarvinen A. 2006. Lactobacillus bacteremia, species identification, and antimicrobial susceptibility of 85 blood isolates. Clin Infect Dis 42:e35e44.
63. Salvana EM,, Frank M. 2006. Lactobacillus endocarditis: case report and review of cases reported since 1992. J Infect 53:e5e10.
64. Citron DM,, Kwok YY,, Appleman MD. 2005. In vitro activity of oritavancin (LY333328), vancomycin, clindamycin, and metronidazole against Clostridium perfringens, Propionibacterium acnes, and anaerobic Gram-positive cocci. Anaerobe 11:9395.
65. Citron DM,, Merriam CV,, Tyrrell KL,, Warren YA,, Fernandez H,, Goldstein EJ. 2003. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria. Antimicrob Agents Chemother 47:23342338.
66. Goldstein EJ,, Citron DM,, Merriam CV,, Warren YA,, Tyrrell KL,, Fernandez HT,, Bryskier A. 2005. Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic gram-positive species, actinomycetes, and lactobacilli. Antimicrob Agents Chemother 49:408413.
67. Leal J,, Gregson DB,, Ross T,, Church DL,, Laupland KB. 2008. Epidemiology of Clostridium species bacteremia in Calgary, Canada, 2000–2006. J Infect 57:198203.
68. Camacho N,, Espinoza C,, Rodríguez C,, Rodríguez E. 2008. Isolates of Clostridium perfringens recovered from Costa Rican patients with antibiotic-associated diarrhoea are mostly enterotoxin-negative and susceptible to first-choice antimicrobials. J Med Microbiol 57:343347.
69. Credito KL,, Ednie LM,, Appelbaum PC. 2008. Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. Antimicrob Agents Chemother 52:365373.
70. Finegold SM,, Song Y,, Liu C,, Hecht DW,, Summanen P,, Kononen E,, Allen SD. 2005. Clostridium clostridioforme: a mixture of three clinically important species. Eur J Clin Microbiol Infect Dis 24:319324.
71. Wootton M,, Bowker KE,, Holt HA,, MacGowan AP. 2002. BAL 9141, a new broad-spectrum pyrrolidinone cephalosporin: activity against clinically significant anaerobes in comparison with 10 other antimicrobials. J Antimicrob Chemother 49:535539.
72. Hecht DW,, Galang MA,, Sambol SP,, Osmolski JR,, Johnson S,, Gerding DN. 2007. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 51:27162719.
73. Curry SR,, Marsh JW,, Shutt KA,, Muto CA,, O’Leary MM,, Saul MI,, Pasculle AW,, Harrison LH. 2009. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 48:425429.
74. Kunishima H,, Chiba J,, Saito M,, Honda Y,, Kaku M. 2013. Antimicrobial susceptibilities of Clostridium difficile isolated in Japan. J Infect Chemother 19:360362.
75. Peláez T,, Cercenado E,, Alcalá L,, Marín M,, Martín-López A,, Martínez-Alarcón J,, Catalán P,, Sánchez-Somolinos M,, Bouza E. 2008. Metronidazole resistance in Clostridium difficile is heterogeneous. J Clin Microbiol 46:30283032.
76. Leeds JA,, Sachdeva M,, Mullin S,, Barnes SW,, Ruzin A. 2013. In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin. J Antimicrob Chemother 69:4144.
77. Brook I,, Wexler HM,, Goldstein EJ. 2013. Antianaerobic antimicrobials: spectrum and susceptibility testing. Clin Microbiol Rev 26:526546.
78. Teng LJ,, Hsueh PR,, Tsai JC,, Liaw SJ,, Ho SW,, Luh KT. 2002. High incidence of cefoxitin and clindamycin resistance among anaerobes in Taiwan. Antimicrob Agents Chemother 46:29082913.
79. Wildeboer-Veloo AC,, Harmsen HJ,, Welling GW,, Degener JE. 2007. Development of 16S rRNA-based probes for the identification of Gram-positive anaerobic cocci isolated from human clinical specimens. Clin Microbiol Infect 13:985992.
80. Veloo AC,, Welling GW,, Degener JE. 2011. Antimicrobial susceptibility of clinically relevant gram-positive anaerobic cocci collected over a three-year period in the Netherlands. Antimicrob Agents Chemother 55:11991203.
81. CLSI. 2014. Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data; Approved Guideline, 4th ed. CLSI M39-A4. Clinical and Laboratory Standards Institute, Wayne, PA.

Tables

Generic image for table
TABLE 1

Methods for susceptibility testing of anaerobic bacteria

Citation: Schuetz A, Hecht D. 2015. Susceptibility Test Methods: Anaerobic Bacteria*, p 1342-1355. In Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, Warnock D (ed), Manual of Clinical Microbiology, Eleventh Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817381.ch75
Generic image for table
TABLE 2

Indications for susceptibility testing of anaerobic bacteria

Citation: Schuetz A, Hecht D. 2015. Susceptibility Test Methods: Anaerobic Bacteria*, p 1342-1355. In Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, Warnock D (ed), Manual of Clinical Microbiology, Eleventh Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817381.ch75
Generic image for table
TABLE 3

Suggested grouping of antimicrobial agents to be considered for testing and reporting on anaerobic organisms, CLSI

Citation: Schuetz A, Hecht D. 2015. Susceptibility Test Methods: Anaerobic Bacteria*, p 1342-1355. In Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, Warnock D (ed), Manual of Clinical Microbiology, Eleventh Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817381.ch75
Generic image for table
TABLE 4

Cumulative antimicrobial susceptibility report for group organisms for isolates collected from selected U.S. hospitals between 1 January 2007 and 31 December 2009

Citation: Schuetz A, Hecht D. 2015. Susceptibility Test Methods: Anaerobic Bacteria*, p 1342-1355. In Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, Warnock D (ed), Manual of Clinical Microbiology, Eleventh Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817381.ch75
Generic image for table
TABLE 5

Cumulative antimicrobial susceptibility report for anaerobic organisms other than group for isolates collected from selected U.S. hospitals between 1 January 2007 and 31 December 2009

Citation: Schuetz A, Hecht D. 2015. Susceptibility Test Methods: Anaerobic Bacteria*, p 1342-1355. In Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, Warnock D (ed), Manual of Clinical Microbiology, Eleventh Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817381.ch75

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error